Results 11 to 20 of about 90,488 (249)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging

Cancer Medicine, 2020
Tamoxifen‐based hormone therapy is central for the treatment of estrogen receptor positive (ER+) breast cancer. However, the acquired tamoxifen resistance, typically co‐exists with hypoxia, remains a major challenge.
Ying Li, Xiaoyu Chen, ZhiWei Zhou, Qing Li, Kenneth D. Westover, Meng Wang, Junjun Liu, Sheng Zhang, Jin Zhang, Bo Xu, Xi Wei   +10 more
doaj   +1 more source

LncRNA SNHG6 sponges miR-101 and induces tamoxifen resistance in breast cancer cells through induction of EMT

Frontiers in Oncology, 2022
Acquired resistance is a major clinical challenge for tamoxifen-based therapy. In this study, we focused on lncRNA SNHG6 which plays a role in chemoresistance of cancer cells, but has never been investigated in the context of tamoxifen resistance.
Mohammad Imran Khan, Mohammad Imran Khan, Aamir Ahmad   +2 more
doaj   +1 more source

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

PLoS ONE, 2014
Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen therapy.
Li Yin, Xin-Tian Zhang, Xiu-Wu Bian, Yu-Ming Guo, Zhao-Yi Wang   +4 more
doaj   +1 more source

Long-Term Use of Tamoxifen Is Associated With a Decreased Subsequent Meningioma Risk in Patients With Breast Cancer: A Nationwide Population-Based Cohort Study

Frontiers in Pharmacology, 2019
Background: Earlier studies have indicated a relatively higher risk of occurring meningioma among female breast cancer survivors and have suggested that tamoxifen might decrease this risk.
Li-Min Sun, Cheng-Li Lin, Cheng-Li Lin, Sean Sun, Chung Y. Hsu, Zonyin Shae, Chia-Hung Kao, Chia-Hung Kao, Chia-Hung Kao   +8 more
doaj   +1 more source

Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells

Scientific Reports, 2020
Tamoxifen resistance is emerging as a big challenge in endocrine therapy of luminal A breast cancer patients. In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using ...
Lama Hamadneh, Rama Abuarqoub, Ala Alhusban, Mohamad Bahader   +3 more
doaj   +1 more source

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

BMC Cancer, 2010
Background The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam,
Lundgren Steinar, Geisler Jürgen, Gjerde Jennifer, Ekse Dagfinn, Varhaug Jan, Mellgren Gunnar, Steen Vidar M, Lien Ernst A   +7 more
doaj   +1 more source

Combination treatment of tamoxifen with risperidone in breast cancer.

PLoS ONE, 2014
Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through
Wei-Lan Yeh, Hui-Yi Lin, Hung-Ming Wu, Dar-Ren Chen   +3 more
doaj   +1 more source

Tamoxifen inhibits TGF-β/Smad pathway and reduces pathological proliferation of human dermal fibroblasts [PDF]

Jichu yixue yu linchuang, 2022
Objective To explore the function and mechanism of tamoxifen, an estrogen receptor modulator, in the pathogenesis of hyperplatic scar. Methods Primary human fibroblasts were isolated and cultured for 4 generations and then aliquated into 3 groups ...
SHI Chun-tian, MAO Shu-ran, PENG Yi-xuan, XIAO Zhi-bo
doaj   +1 more source

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer

EMBO Molecular Medicine, 2019
Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains ...
Liping Ye, Chuyong Lin, Xi Wang, Qiji Li, Yue Li, Meng Wang, Zekun Zhao, Xianqiu Wu, Dongni Shi, Yunyun Xiao, Liangliang Ren, Yunting Jian, Meisongzhu Yang, Ruizhang Ou, Guangzheng Deng, Ying Ouyang, Xiangfu Chen, Jun Li, Libing Song   +18 more
doaj   +1 more source

Polysaccharide Peptide Extract From Coriolus versicolor Increased Tmax of Tamoxifen and Maintained Biochemical Serum Parameters, With No Change in the Metabolism of Tamoxifen in the Rat

Frontiers in Pharmacology, 2022
Background: Polysaccharide peptide (PSP) extract of Coriolus versicolor (L.) Quél. (1886) (Trametes; Polyporaceae) is increasingly used in cancer to support the immune system.
Valentina Razmovski-Naumovski, Valentina Razmovski-Naumovski, Valentina Razmovski-Naumovski, Benjamin Kimble, Daunia Laurenti, Daunia Laurenti, Srinivas Nammi, Srinivas Nammi, Hisayoshi Norimoto, Kelvin Chan, Kelvin Chan   +10 more
doaj   +1 more source